MIRALAX (polyethylene glycol 3350) by Bayer is osmotic activity [moa]. First approved in 2006.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
MIRALAX is an oral osmotic laxative containing polyethylene glycol 3350 that draws water into the colon to promote bowel movements. It is used to treat occasional constipation in patients seeking a gentle, non-stimulant option. The drug works through osmotic activity, making it suitable for patients of all ages including children.
Product is in late-stage lifecycle with 30% competitive pressure, signaling a smaller, defensive marketing team focused on market maintenance rather than growth expansion.
Osmotic Activity
Osmotic Laxative
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)
Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
Worked on MIRALAX at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MIRALAX offers limited career growth opportunities given the product's approaching loss of exclusivity and absence of clinical development activity. Roles on this team tend to be maintenance-focused, emphasizing market defense and operational efficiency rather than innovation or expansion.